Paper9728893
The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.
Gorski JC and 5 others. Clin Pharmacol Ther, 1998. Cited by 350 papers, by iCite.
Cite this record
ConductScience Library. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Papers, record 9728893. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9728893
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.
- PubMed
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Anxiety Agents | Major topic |
| Anti-Bacterial Agents | Major topic |
| Aryl Hydrocarbon Hydroxylases | Major topic |
| Clarithromycin | Major topic |
| Cytochrome P-450 Enzyme System | Major topic |
| Intestines | Major topic |
| Liver | Major topic |
| Midazolam | Major topic |
| Oxidoreductases, N-Demethylating | Major topic |
| Adult | |
| Biological Availability | |
| Cytochrome P-450 CYP3A | |
| Drug Administration Schedule | |
| Drug Interactions | |
| Female | |
| Humans | |
| Male | |
| Reference Values | |
| Sex Characteristics |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| AG13718 | NIA NIH HHS | United States | R01AG013718 | PubMed and NIH | NIH RePORTER |
| M01 RR00750 | NCRR NIH HHS | United States | M01RR000750 | PubMed and NIH | NIH RePORTER |
| T32GM08425 | NIGMS NIH HHS | United States | T32GM008425 | PubMed and NIH | NIH RePORTER |
Cited by108
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 350 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42399716 | Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist. | Clin Pharmacol Ther | 2026 | https://conductscience.org/library/papers/42399716 | PubMed |
| 42357334 | CYP3A-Mediated Metabolism of Zastaprazan in Humans and Associated Drug-Drug Interactions. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42357334 | PubMed |
| 41369158 | Method development and validation for simultaneous analysis of four bile acids as CYP3A drug-drug interaction biomarkers. | Bioanalysis | 2025 | https://conductscience.org/library/papers/41369158 | PubMed |
| 41270461 | Canine duodenal organoids as a functional platform for intestinal CYP regulation and drug metabolism studies. | Drug Metab Dispos | 2025 | https://conductscience.org/library/papers/41270461 | PubMed |
| 41117965 | Biological sex differences in pharmacokinetics and adverse drug reactions. | Naunyn Schmiedebergs Arch Pharmacol | 2026 | https://conductscience.org/library/papers/41117965 | PubMed |
| 40869119 | Natural Polymorphic Variants in the CYP450 Superfamily: A Review of Potential Structural Mechanisms and Functional Consequences. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40869119 | PubMed |
| 40136716 | Sexual Dimorphism in Cardiometabolic Diseases: From Development to Senescence and Therapeutic Approaches. | Cells | 2025 | https://conductscience.org/library/papers/40136716 | PubMed |
| 39313741 | Pharmacokinetic Model of Drug Interaction of Tacrolimus with Combined Administration of CYP3A4 Inhibitors Voriconazole and Clarithromycin After Bone Marrow Transplantation. | Eur J Drug Metab Pharmacokinet | 2024 | https://conductscience.org/library/papers/39313741 | PubMed |
| 39072249 | Sedation reversal trends at outpatient ambulatory endoscopic center vs in-hospital ambulatory procedure center using a triage protocol. | World J Gastrointest Endosc | 2024 | https://conductscience.org/library/papers/39072249 | PubMed |
| 37361220 | Pharmacokinetic interaction of voriconazole and clarithromycin in Pakistani healthy male volunteers: a single dose, randomized, crossover, open-label study. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/37361220 | PubMed |
| 36611556 | What Is Known about Midazolam? A Bibliometric Approach of the Literature. | Healthcare (Basel) | 2022 | https://conductscience.org/library/papers/36611556 | PubMed |
| 36210839 | Prediction of pyrotinib exposure based on physiologically-based pharmacokinetic model and endogenous biomarker. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/36210839 | PubMed |
| 35903521 | Sedation level with midazolam: A pediatric surgery approach. | Saudi Pharm J | 2022 | https://conductscience.org/library/papers/35903521 | PubMed |
| 34783193 | Physiologically-based pharmacokinetic modeling to predict CYP3A4-mediated drug-drug interactions of finerenone. | CPT Pharmacometrics Syst Pharmacol | 2022 | https://conductscience.org/library/papers/34783193 | PubMed |
| 34383278 | Effects of Repeated Oral Administration of Esaxerenone on the Pharmacokinetics of Midazolam in Healthy Japanese Males. | Eur J Drug Metab Pharmacokinet | 2021 | https://conductscience.org/library/papers/34383278 | PubMed |
| 34003603 | The role of sex, age and genetic polymorphisms of CYP enzymes on the pharmacokinetics of anticholinergic drugs. | Pharmacol Res Perspect | 2021 | https://conductscience.org/library/papers/34003603 | PubMed |
| 33572963 | Pharmacokinetic Estimation Models-based Approach to Predict Clinical Implications for CYP Induction by Calcitriol in Human Cryopreserved Hepatocytes and HepaRG Cells. | Pharmaceutics | 2021 | https://conductscience.org/library/papers/33572963 | PubMed |
| 32973880 | Inherited and Acquired Determinants of Hepatic CYP3A Activity in Humans. | Front Genet | 2020 | https://conductscience.org/library/papers/32973880 | PubMed |
| 32725383 | Volume of Distribution is Unaffected by Metabolic Drug-Drug Interactions. | Clin Pharmacokinet | 2021 | https://conductscience.org/library/papers/32725383 | PubMed |
| 32244748 | The Segregated Intestinal Flow Model (SFM) for Drug Absorption and Drug Metabolism: Implications on Intestinal and Liver Metabolism and Drug-Drug Interactions. | Pharmaceutics | 2020 | https://conductscience.org/library/papers/32244748 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CYP3A4 | 1576 | PubTator's text mining | https://conductscience.org/library/genes/1576 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/9728893
GET https://conductscience.org/api/papers/v1/9728893/cited_by?page=2